Regulatory perspective on clinical trials and end points for female sexual dysfunction, in particular, hypoactive sexual desire disorder: Formulating recommendations in an environment of evolving clinical science

International Journal of Impotence Research

Volumn 19, Issue 1, 2007, Pages 30-36

  Shames, D ^a   Monroe, S E ^a   Davis, D ^a   Soule, L ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Female sexual dysfunction (FSD); Hypoactive sexual desire disorder (HSDD); Testosterone therapy in women

Indexed keywords

ESTROGEN; GESTAGEN; SILDENAFIL; TESTOSTERONE;

BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL STUDY; CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DYSPAREUNIA; FEMALE SEXUAL DYSFUNCTION; FOOD AND DRUG ADMINISTRATION; HORMONE SUBSTITUTION; HUMAN; HYPOACTIVE SEXUAL DESIRE DISORDER; METABOLIC SYNDROME X; NOMENCLATURE; ORGASM DISORDER; POLICY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SEXUAL AROUSAL; TESTOSTERONE BLOOD LEVEL; TREATMENT RESPONSE; UNITED STATES;

CLINICAL TRIALS; DRUG INDUSTRY; FEMALE; HUMANS; LEGISLATION, DRUG; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; TESTOSTERONE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33846073187     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901481     Document Type: Review

References (8)

1. Federal Food, Drug, and Cosmetic Act. Section 505(d), 21 U.S.C. 351 1962.
2. US Food and Drug Administration. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. March 2004 Available from: http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html.
3. US Food and Drug Administration. Good Review Management Principles and Practices for PDUFA Products. April 2005 Available from: http://www.fda.gov/cder/guidance/5812fnl.pdf.
4. Allen SS. Regulatory and drug development issues related to female sexual dysfunction. J Sex Marital Ther 2002; 28 (Suppl 1): 11-16.
5. US Food and Drug Administration. Female Sexual Dysfunction: Clinical Development of Drug Products for Treatment. May 2000 Available from: http://www.fda.gov/cder/guidance/3312dft.pdf.
6. Temple RJ. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 1999; 282: 790-795.
7. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
8. Althof SE, Rosen RC, DeRogatis L, Corty E, Quirk F, Symonds T. Outcome measurement in female sexual dysfunction clinical trials: Review and Recommendations. J Sex Marital Ther 2005; 31: 153.